$ALT
Altimmune Inc

2015 Q1 Form 10-Q Financial Statement

#000114420415028415 Filed on May 07, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q1
Revenue $7.070M $3.740M
YoY Change 89.04% -42.28%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.200M $2.680M
YoY Change -17.91% 17.54%
% of Gross Profit
Research & Development $1.610M $3.427M
YoY Change -53.02% -34.52%
% of Gross Profit
Depreciation & Amortization $37.11K $39.94K
YoY Change -7.09% -24.07%
% of Gross Profit
Operating Expenses $5.908M $6.144M
YoY Change -3.85% -18.79%
Operating Profit $1.161M -$2.402M
YoY Change -148.34% 120.21%
Interest Expense $25.33K $69.87K
YoY Change -63.76% -29.98%
% of Operating Profit 2.18%
Other Income/Expense, Net $322.1K $173.1K
YoY Change 86.05% -117.13%
Pretax Income $1.483M -$2.229M
YoY Change -166.55% 6.05%
Income Tax $20.00K $30.00K
% Of Pretax Income 1.35%
Net Earnings $1.463M -$2.258M
YoY Change -164.8% 6.96%
Net Earnings / Revenue 20.7% -60.39%
Basic Earnings Per Share $0.02 -$0.04
Diluted Earnings Per Share $0.02 -$0.04
COMMON SHARES
Basic Shares Outstanding 63.63M shares 53.04M shares
Diluted Shares Outstanding 63.98M shares 53.04M shares

Balance Sheet

Concept 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.70M $9.500M
YoY Change 65.26% -26.36%
Cash & Equivalents $15.72M $9.535M
Short-Term Investments $6.400M $6.400M
Other Short-Term Assets $400.0K $400.0K
YoY Change 0.0% -33.33%
Inventory
Prepaid Expenses
Receivables $6.600M $1.600M
Other Receivables $0.00 $0.00
Total Short-Term Assets $22.70M $11.59M
YoY Change 95.93% -39.24%
LONG-TERM ASSETS
Property, Plant & Equipment $300.0K $380.6K
YoY Change -21.17% -16.7%
Goodwill $2.348M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $59.13K
YoY Change 69.11% -40.62%
Total Long-Term Assets $2.800M $2.788M
YoY Change 0.42% -4.02%
TOTAL ASSETS
Total Short-Term Assets $22.70M $11.59M
Total Long-Term Assets $2.800M $2.788M
Total Assets $25.50M $14.37M
YoY Change 77.4% -34.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $500.0K $471.8K
YoY Change 5.98% -63.42%
Accrued Expenses $3.400M $1.900M
YoY Change 78.95% -42.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $498.2K $1.000M
YoY Change -50.18% 0.0%
Total Short-Term Liabilities $4.500M $3.465M
YoY Change 29.85% -55.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $485.4K
YoY Change -100.0% -66.76%
Other Long-Term Liabilities $900.0K $602.4K
YoY Change 49.4% 3.82%
Total Long-Term Liabilities $900.0K $1.088M
YoY Change -17.26% -46.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.500M $3.465M
Total Long-Term Liabilities $900.0K $1.088M
Total Liabilities $5.400M $6.049M
YoY Change -10.73% -49.72%
SHAREHOLDERS EQUITY
Retained Earnings -$218.8M -$212.6M
YoY Change 2.93% 5.91%
Common Stock $239.1M $221.1M
YoY Change 8.11% 4.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.02M $8.325M
YoY Change
Total Liabilities & Shareholders Equity $25.47M $14.37M
YoY Change 77.16% -34.58%

Cashflow Statement

Concept 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income $1.463M -$2.258M
YoY Change -164.8% 6.96%
Depreciation, Depletion And Amortization $37.11K $39.94K
YoY Change -7.09% -24.07%
Cash From Operating Activities -$2.713M -$2.294M
YoY Change 18.28% -980.97%
INVESTING ACTIVITIES
Capital Expenditures $35.35K $37.05K
YoY Change -4.58% 45.48%
Acquisitions
YoY Change
Other Investing Activities $10.00K $10.00K
YoY Change 0.0%
Cash From Investing Activities -$27.75K -$29.05K
YoY Change -4.47% 14.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $84.33K $2.719M
YoY Change -96.9% 4990.87%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$165.7K $1.377M
YoY Change -112.03% -2382.01%
NET CHANGE
Cash From Operating Activities -$2.713M -$2.294M
Cash From Investing Activities -$27.75K -$29.05K
Cash From Financing Activities -$165.7K $1.377M
Net Change In Cash -$2.907M -$945.7K
YoY Change 207.38% -641.71%
FREE CASH FLOW
Cash From Operating Activities -$2.713M -$2.294M
Capital Expenditures $35.35K $37.05K
Free Cash Flow -$2.749M -$2.331M
YoY Change 17.91% -1092.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
498203 USD
CY2014Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
746146 USD
CY2015Q1 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
49463 USD
CY2014Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
178509 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2581789 USD
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
493137 USD
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
6367 USD
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
6360 USD
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
239064585 USD
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
238780633 USD
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-227782 USD
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-229528 USD
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-218819925 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220283320 USD
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
20023245 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
18274145 USD
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25465298 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21978241 USD
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63674326 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63603303 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63674326 shares
CY2015Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
72674 USD
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
70326 USD
CY2015Q1 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
1927877 USD
CY2014Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
USD
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63603303 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q1 us-gaap Depreciation
Depreciation
37106 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
5907662 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
6144391 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1161084 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2401866 USD
CY2015Q1 us-gaap Interest Expense
InterestExpense
25325 USD
CY2014Q1 us-gaap Interest Expense
InterestExpense
69872 USD
CY2015Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
338245 USD
CY2014Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
242641 USD
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9196 USD
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
362 USD
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
322116 USD
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
173131 USD
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1483200 USD
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2228735 USD
CY2015Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
19805 USD
CY2014Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
29705 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
1463395 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2258440 USD
CY2015Q1 us-gaap Restructuring Charges
RestructuringCharges
2060809 USD
CY2014Q1 us-gaap Restructuring Charges
RestructuringCharges
USD
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63633290 shares
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53044119 shares
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63979859 shares
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53044119 shares
CY2015Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1277017 USD
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2258440 USD
CY2015Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1746 USD
CY2014Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-657 USD
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1465141 USD
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2259097 USD
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
199627 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
528878 USD
CY2015Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
19805 USD
CY2014Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
29705 USD
CY2015Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
10933 USD
CY2014Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
26591 USD
CY2015Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
7600 USD
CY2014Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
5393 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5863332 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1427113 USD
CY2015Q1 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
296828 USD
CY2014Q1 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-549629 USD
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
253779 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
178704 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
146740 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-656373 USD
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
230186 USD
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1274906 USD
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
USD
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-279462 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2713361 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2294064 USD
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35352 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
37050 USD
CY2015Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
7600 USD
CY2014Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27752 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29050 USD
CY2015Q1 us-gaap Proceeds From Repayments Of Other Long Term Debt
ProceedsFromRepaymentsOfOtherLongTermDebt
-249999 USD
CY2014Q1 us-gaap Proceeds From Repayments Of Other Long Term Debt
ProceedsFromRepaymentsOfOtherLongTermDebt
-249999 USD
CY2015Q1 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
USD
CY2014Q1 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-1091740 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
84332 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2719184 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-165667 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1377445 USD
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-11615 USD
CY2014Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-590 USD
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2918395 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-946259 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10480979 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9534720 USD
CY2015Q1 us-gaap Interest Paid
InterestPaid
14849 USD
CY2014Q1 us-gaap Interest Paid
InterestPaid
43287 USD
CY2015Q1 us-gaap Restructuring Reserve Period Increase Decrease
RestructuringReservePeriodIncreaseDecrease
1938631 USD
CY2014Q1 us-gaap Restructuring Reserve Period Increase Decrease
RestructuringReservePeriodIncreaseDecrease
USD
CY2015Q1 pip Billed And Unbilled Accounts Receivable Net
BilledAndUnbilledAccountsReceivableNet
6600000 USD
CY2015Q1 pip Additional Common Stock Aggregate Gross Sales
AdditionalCommonStockAggregateGrossSales
3000000 USD
CY2015Q1 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
2000000 USD
CY2015Q1 us-gaap Dilutive Securities
DilutiveSecurities
-185774 USD
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Use of Estimates</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.&#160;Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</font></p> </div>
CY2015Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1462788 USD
CY2015Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
-3 USD
CY2015Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2015Q1 pip Share Based Compensation Extension Of Exercise Period
ShareBasedCompensationExtensionOfExercisePeriod
75000 USD
CY2015Q1 pip Incremental Common Shares Attributable To Dilutive Effect Of Call Options
IncrementalCommonSharesAttributableToDilutiveEffectOfCallOptions
327020 shares
CY2015Q1 pip Incremental Common Shares Attributable To Dilutive Effect Of Warrants
IncrementalCommonSharesAttributableToDilutiveEffectOfWarrants
19550 shares
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4900000 shares
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12600000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
12000 shares
CY2015Q1 pip Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod
117500 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1217755 shares
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1000000 USD
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2015Q1 pip Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Annual Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate
0.12 pure
CY2015Q1 pip Share Based Compensation Reversal From Stock Option Forfeitures
ShareBasedCompensationReversalFromStockOptionForfeitures
129000 USD
CY2015Q1 pip Share Based Compensation Reversal Net
ShareBasedCompensationReversalNet
54000 USD
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
199627 USD
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
528878 USD
CY2015Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
607 USD
CY2015Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
469434 USD
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1922781 shares
CY2014Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5620128 shares
CY2015Q1 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
113000000 USD
CY2015Q1 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
194600000 USD
CY2015Q1 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
113100000 USD
CY2015Q1 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
81500000 USD
CY2009Q3 pip Warrant Expiration Date
WarrantExpirationDate
2015-01-28
CY2015Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
500008 USD
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Trading Symbol
TradingSymbol
PIP
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
PHARMATHENE, INC
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001326190
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
63792026 shares
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 dei Document Type
DocumentType
10-Q

Files In Submission

Name View Source Status
0001144204-15-028415-index-headers.html Edgar Link pending
0001144204-15-028415-index.html Edgar Link pending
0001144204-15-028415.txt Edgar Link pending
0001144204-15-028415-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
pip-20150331.xml Edgar Link completed
pip-20150331.xsd Edgar Link pending
pip-20150331_cal.xml Edgar Link unprocessable
pip-20150331_def.xml Edgar Link unprocessable
pip-20150331_lab.xml Edgar Link unprocessable
pip-20150331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v408605_10q.htm Edgar Link pending
v408605_ex10-3013.htm Edgar Link pending
v408605_ex10-3014.htm Edgar Link pending
v408605_ex10-3015.htm Edgar Link pending
v408605_ex10-3016.htm Edgar Link pending
v408605_ex31-1.htm Edgar Link pending
v408605_ex31-2.htm Edgar Link pending
v408605_ex32-1.htm Edgar Link pending
v408605_ex32-2.htm Edgar Link pending